Steroid-resistant remitting seronegative symmetrical synovitis with pitting oedema associated with gout treated with etanercept.

Disclosure statement: M.K. has received speaking fees from Eisai, Chugai Pharma, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Janssen Pharma, Astellas Pharma, Takeda Pharma and Abbott Japan. M.T. has received speaking fees from Mitsubishi Tanabe Pharma, Astellas Pharma and Janssen Pharma. M.M. has received speaking fees from Pfizer. S.Y. has received speaking fees from Eisai, Mitsubishi Tanabe Pharma, Pfizer, Astellas Pharma and Takeda Pharma and has received research grant support from Astellas Pharma, Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai, Pfizer and Janssen Pharma. Y.S. has received speaking fees from Mitsubishi Tanabe Pharma and Takeda Pharma. Y.M. has received speaking fees from Chugai Pharma, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Astellas Pharma, Takeda Pharma, Janssen Pharma, Santen Pharma, Bristol-Myers Squibb, Ono Pharma, Kissei Pharma, Actelion Pharma and Abbott Japan and has received research grant support from Teijin Pharma, Astellas Pharma, Bristol-Myers Squibb, Mitsubishi Tanabe Pharma, Chugai Pharma, Takeda Pharma and Eisai. All other authors have declared no conflicts of interest.